Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCis Pharma, a privately-held drug development company, has started a new Phase IIa clinical testing of ProtoCure emulsion cream, the company's novel topical drug for dermatology.
Subscribe to our email newsletter
The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis. The subjects will apply ProtoCure emulsion cream up to four weeks to the skin areas affected by the disease.
Lasse Leino, CEO of BioCis Pharma, said: “With the commencement of this clinical trial we expand our clinical activities to a new dermatological indication. Together with the ongoing Phase IIa clinical trial in patients with mild to moderate atopic dermatitis, this first study in psoriasis will quickly enable us to obtain data to support our full-scale Phase II clinical development program of ProtoCure emulsion cream in chronic skin inflammation. We expect to get results from both studies by third quarter of 2009.”